Anascorp

Name: Anascorp

Adverse Effects

1-10%

Vomiting (4.7%)

Pyrexia (4.1%)

Rash (2.7%)

Nausea (2.1%)

Pruritus (2%)

Headache (1.9%)

Rhinorrhea (1.8%)

Myalgia (1.6%)

Fatigue (1.6%)

Cough (1.4%)

Diarrhea (1.3%)

Lethargy (1.1%)

<1%

Serum sickness (0.5%)

Postmarketing Reports

Chest tightness

Palpitation

Eye edema

Respiratory distress

Warnings

Contraindications

None listed by manufacturer

Cautions

Severe hypersensitivity reactions, including anaphylaxis, are possible; prepare for monitoring and management of allergic reactions, particularly with a history of hypersensitivity to equine proteins or who have received previous antivenins containing equine proteins

Readiness with IV therapy using epinephrine, corticosteroids, and diphenhydramine is recommended during the infusion

Delayed allergic reactions (serum sickness, 0.5% incidence) may occur; monitor with follow-up visit

Made from equine plasma and may contain infectious agents (eg, viruses)

Localized reactions and generalized myalgias reported with cresol, as an injectable excipient contained in Anascorp

Administration

IV Preparation

Reconstitute contents of each vial with 5 mL of sterile normal saline and mix by continuous gentle swirling

Initial infusion (ie, 3 vials): Combine contents of reconstituted vials promptly and further dilute to a total volume of 50 mL with sterile normal saline

Additional doses: Further dilute reconstituted vial to total volume of 50 mL with sterile normal saline

Inspect solution visually for particulate matter and discoloration prior to administration; do not use if turbid

IV Administration

Infuse IV over 10 minutes

Monitor patient closely during and up to 60 minutes following completion of infusion to determine if clinically important signs of envenomation have resolved

Storage

Available as a sterile, lyophilized preparation in a single-use vial

Store at room temperature (up to 25 ºC [77 ºF])

Temperature excursions are permitted up to 40 ºC (104ºF)

Do not freeze

Discard partially used vials

US Brand Name

  1. Anascorp

Indications

Anascorp® [Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation.

Patient information

Advise patients to contact the physician or emergency department immediately if they experience any signs and symptoms of delayed allergic reactions or serum sickness up to 14 days following hospital discharge. Symptoms include rash, pruritus, joint pain, arthralgia, fever, lymphadenopathy, and malaise.

What do I need to tell my doctor BEFORE I take Anascorp?

  • If you have an allergy to antivenin (centruroides) or any other part of Anascorp (immune F(ab’) (equine)).
  • If you have an allergy to horses or horse serum.
  • If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.

This medicine may interact with other drugs or health problems.

Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this medicine with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.

What are some other side effects of Anascorp?

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

  • Upset stomach or throwing up.
  • Mild fever.

These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.

Pregnancy

Information about this scorpion-centruroides-immune-fab2-intravenous-route
Pregnancy Category Explanation
All Trimesters C Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breastfeeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

(web3)